The Merck Group Website
The Merck Group Website

Merck Serono at a glance

Merck Serono global division headquarters in Geneva, Switzerland
Merck Serono global division headquarters in Geneva, Switzerland
Group: Largest division of Merck KGaA
Established: January 5, 2007
Business: Biopharmaceuticals
Employees: 16,867 (31.12.2011)
Total revenues: € 5.9 billion in 2011
Headquarters: Geneva, Switzerland
Global reach: Products commercialized in 150 countries
 

Key products*
Key sales figures
Therapeutic AreaKey indications

Oncology
Erbitux® (cetuximab)

- Metastatic colorectal cancer and locally advanced or recurrent and/or metastatic squamous cell carcinoma of the head and neck
Neurodegenerative Diseases
Rebif® (interferon beta-1a)		- Early signs of multiple sclerosis 
- Relapsing multiple sclerosis

Fertility
Complete portfolio of drugs including gonadotropic hormones used in the treatment of infertility
GONAL-f®
Ovidrel®
Luveris®
Cetrotide®
Crinone®
Pergoveris®

- Various indications in the treatment of infertility        

Endocrinology
Saizen® (somatropin for injection)





Serostim® (somatropin for injection)

Kuvan® (sapropterin dihydrochloride)


 

EGRIFTA™ (tesamorelin for injection)

- Child and adult growth hormone deficiency
- Children born small for gestational age
- Turner syndrome
- Chronic renal failure

- HIV-associated wasting (U.S. market only)

- Treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients

- Excess abdominal fat in HIV-infected patients with lipodystrophy (abdominal lipohypertrophy)
  (U.S. market only) 

CardioMetabolic Care & General Medicine

Glucophage® (metformin hydrochloride)


Concor® family of products containing bisoprolol


Euthyrox® (levothyroxine sodium), thyroid hormones


Neurobion – Vitamin B complex

- Type II diabetes

- Cardiovascular diseases (hypertension, coronary artery disease, chronic heart failure)

- Thyroid disorders

- Treatment or prevention of Vitamin B deficiency

* Merck Serono’s marketed products are available in various countries and regions of the world under different trademarks.  Depending on the region, they may be approved or cleared by a government regulatory body for sale or use with different indications and restrictions.  For detailed information on the products and their approved indications, please refer to the respective publicly available full prescribing information

€ million2011  2010∆ in %
Total revenues 5,920 5,7542.9
Gross margin 4,888 4,7932.0
R&D 1,225 1,1675.0
Operating result 304 565-46
Exception items 25 69-63
Free cash flow 1,475 1,29814
Underlying free cash flow 1,205 1,308-7.8
ROS in % 5.1 9.8
Underlying Core OR % of Revenues 22.6 22.2 
 
top
Merck Serono S.A.

DOWNLOADS

Financial Results

SERVICES